Amicus Therapeutics to Present at the Cowen 42nd Annual Health Care Conference
Amicus Therapeutics (Nasdaq: FOLD) will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 9:10 a.m. E.T.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Amicus Therapeutics (Nasdaq: FOLD) will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 9:10 a.m. E.T. A live audio webcast of the event will be available on the company’s investor website.
Amicus Therapeutics is focused on developing innovative medicines for rare metabolic diseases, showcasing its commitment to patient care through a robust pipeline of treatments.
Details
News Market Reaction – FOLD
The recorded move for FOLD in the trading session of this news was +0.86%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PHILADELPHIA, March 01, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 9:10 a.m. E.T.
A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow us on Twitter and LinkedIn.
CONTACT:
Investors:
Amicus Therapeutics
Andrew Faughnan
Executive Director, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809
Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Affairs & Communications
dmoore@amicusrx.com
(609) 662-5079
FOLD-G
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.